Gyre Therapeutics, Inc.
GYRE
$8.44
-$0.37-4.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.67% | -20.45% | -13.99% | 8.99% | -4.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.67% | -20.45% | -13.99% | 8.99% | -4.67% |
| Cost of Revenue | -5.84% | -19.09% | -28.51% | -12.98% | -8.15% |
| Gross Profit | 3.08% | -20.51% | -13.44% | 10.03% | -4.50% |
| SG&A Expenses | -15.83% | 16.16% | -9.50% | 9.88% | 19.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.86% | 10.26% | -9.82% | 4.57% | 8.29% |
| Operating Income | 112.78% | -66.84% | -34.42% | 21.11% | -275.06% |
| Income Before Tax | 100.77% | -64.87% | 3.09% | 99.03% | -8,690.92% |
| Income Tax Expenses | -70.96% | -70.80% | -28.17% | 23.95% | -47.56% |
| Earnings from Continuing Operations | 100.56% | -61.97% | 20.37% | 135.59% | -3,982.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2,203.45% | 50.99% | 47.31% | -21.79% | 97.12% |
| Net Income | 99.90% | -71.73% | 90.39% | 235.65% | -2,802.80% |
| EBIT | 112.78% | -66.84% | -34.42% | 21.11% | -275.06% |
| EBITDA | 123.23% | -63.85% | -33.86% | 22.24% | -323.66% |
| EPS Basic | 99.91% | -79.04% | 41.92% | 156.37% | -2,444.79% |
| Normalized Basic EPS | 97.81% | -85.74% | 19.71% | 111.76% | -321.27% |
| EPS Diluted | 99.76% | -73.80% | -70.50% | 201.67% | -2,430.91% |
| Normalized Diluted EPS | 97.81% | -85.21% | 21.72% | 162.35% | -321.27% |
| Average Basic Shares Outstanding | 18.45% | 34.68% | 34.46% | 30.95% | 14.11% |
| Average Diluted Shares Outstanding | 18.45% | 30.08% | 32.22% | 5.50% | 14.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |